NCT07509359 Comparing Basilic and Cephalic Vein Approaches for Midline Catheter Placement in Children
| NCT ID | NCT07509359 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Seoul National University Hospital |
| Condition | Vascular Access Device Complications |
| Study Type | INTERVENTIONAL |
| Enrollment | 96 participants |
| Start Date | 2026-04-01 |
| Primary Completion | 2026-04-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 96 participants in total. It began in 2026-04-01 with a primary completion date of 2026-04-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective randomized controlled trial aims to compare basilic vein and cephalic vein approaches for midline catheter placement in pediatric patients undergoing general anesthesia. Participants aged 2 to 17 years who require midline catheter insertion will be randomly assigned 1:1 to either the basilic vein group or the cephalic vein group. The primary outcome is the clinical blood sampling success rate during the catheter dwell period, defined as successful aspiration of ≥2 mL of blood through the midline catheter at least once without additional venipuncture. Secondary outcomes include operator-rated difficulty, number of puncture attempts, first attempt cannulation success rate, vein diameter and depth, catheter dwell time, catheter-related complications, and patient satisfaction. A total of 96 participants (48 per arm) will be enrolled at Seoul National University Children's Hospital.
Eligibility Criteria
Inclusion Criteria: * Age 2-17 years undergoing general anesthesia * Midline catheter placement deemed necessary by attending anesthesiologist (≥1 of: expected ≥2 postop blood draws; expected blood loss ≥40% EBV; continuous antibiotic therapy; hospitalization ≥7 days; surgical team request) Exclusion Criteria: * Need for central venous catheter per surgical team * Coagulopathy * History of severe thrombosis * Other investigator-determined ineligibility
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07509359 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, up to 17 Years, studying Vascular Access Device Complications. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07509359 currently recruiting?
Yes, NCT07509359 is actively recruiting participants. Contact the research team at psb3237@naver.com for enrollment information.
Where is the NCT07509359 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT07509359 clinical trial?
NCT07509359 is sponsored by Seoul National University Hospital. The trial plans to enroll 96 participants.